David Millan, PhD
David Millan, PhD, is the vice president of chemistry at Foghorn Therapeutics. Before joining the company, David was the head of medicinal chemistry at FORMA Therapeutics, where he helped build the medicinal chemistry group and led programs in epigenetics and metabolism through to IND.
Prior to this appointment, David held positions of increasing responsibility at Pfizer in the U.K., making significant contributions to the discovery of multiple clinical candidates in respiratory and pain therapeutics. David began his career at Vertex Pharmaceuticals in the U.K., working as a medicinal chemist.
David holds a BSc with honors (first class) and a PhD in chemistry from Flinders University, in Adelaide, Australia. He completed postdoctoral research at University of Nottingham, in the laboratory of Gerald Pattenden, working on the total synthesis of the complex marine natural product phorboxazole A.